Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
Randomized clinical study evaluating superiority in platelet inhibition after administration
of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated
tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST
elevation myocardial infarction.